Providence Business News

Bragar Eagel & Squire, P.C. Is Investigating MINISO, Digital World, Verano, and Phathom and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022
FDA, U.S. Securities and Exchange Commission, Providence Business News, NYSE, GLOBE, ADS, Trump, Bloomberg, SV, Board, American depositary receipt, Canadian Securities Exchange, Notice, Wanderland, MNSO, Company, Audit committee, SPAC, NASDAQ, Social media, News, Black–Scholes model, Digital, IPO, App Store (iOS/iPadOS), Audit, Online gambling, Security (finance), P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On July 26, 2022, Blue Orca Capital (Blue Orca) published a short report concerning MINISO.
  • For more information on the Phathom investigation go to: https://www.bespc.com/cases/PHAT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, August 5, 2022
Class Action Lawsuit, Professional Services, Legal, FDA, Company, P.C, News, Telephone, Providence Business News, NASDAQ, Jeanne Eagels (film), Private investigator, Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) on behalf of Phathom stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) on behalf of Phathom stockholders.
  • Our investigation concerns whether Phathom has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Phathoms stock price fell $2.61 per share, or 28%, to close at $6.46 per share on August 2, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 4, 2022
Legal, Professional Services, P.C, Providence Business News, Jeanne Eagels (film), Company, News, Telephone, NASDAQ, FDA, Private investigator, Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) on behalf of Phathom stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) on behalf of Phathom stockholders.
  • Our investigation concerns whether Phathom has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Phathoms stock price fell $2.61 per share, or 28%, to close at $6.46 per share on August 2, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, August 3, 2022
Class Action Lawsuit, Professional Services, Legal, Ethics, Providence Business News, Company, News, Suite, Certification, NASDAQ, FDA, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Phathom issued a press release on August 2, 2022, titled: Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, August 2, 2022
Class Action Lawsuit, Professional Services, Legal, NASDAQ, Ethics, News, Certification, Suite, FDA, Company, Providence Business News, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Phathom issued a press release on August 2, 2022, titled: Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

EQUITY ALERT: Rosen Law Firm Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – PHAT

Retrieved on: 
Tuesday, August 2, 2022
Class Action Lawsuit, Professional Services, Legal, Titan, Twitter, WHY, Advertising, NASDAQ, News, Facebook, I-Space (Chinese company), FDA, Company, LinkedIn, Providence Business News, TO, Security (finance)

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Jace Stirling Joins Embrace Home Loans as Regional Sales Manager

Retrieved on: 
Monday, August 1, 2022
Freddie Mac, Fortune, University, Industry, Embrace, CEO, Fannie Mae, History of the University of Maryland, College Park, SunTrust Banks, Embrace Home Loans, The Last Best Place, Providence Business News, Horse, Veteran, Board, News, Mortgage Bankers Association, Leadership, Quality of life, Washington metropolitan area, Loyola University, Director, Technology, FHA, SVP, Wells Fargo, District, Real estate, Management, U.S. Bancorp

MIDDLETOWN, R.I., Aug. 1, 2022 /PRNewswire/ -- Embrace Home Loans, a leading national mortgage lender, announced that James "Jace" Stirling has been named regional sales manager for the company's Southeast region. Stirling is an experienced relationship manager who has led and developed sales teams at major banks and mortgage lenders. 

Key Points: 
  • MIDDLETOWN, R.I., Aug. 1, 2022 /PRNewswire/ -- Embrace Home Loans , a leading national mortgage lender, announced that James "Jace" Stirling has been named regional sales manager for the company's Southeast region.
  • Stirling is an experienced relationship manager who has led and developed sales teams at major banks and mortgage lenders.
  • Jace will be a tremendous asset as Embrace continues to expand around the country," said Dennis Hardiman, CEO of Embrace Home Loans.
  • In his new role, Stirling will be leading and developing the Embrace sales teams in all states from Virginia to Florida, including Alabama.

Embrace Home Loans' Lisbeth Najarro Named a Top Latino Mortgage Originator

Retrieved on: 
Wednesday, July 27, 2022
Fortune, Most, Embrace, Embrace Home Loans, The Last Best Place, Providence Business News, Antonio Najarro, National Association, News, Club, District, Real estate

MIDDLETOWN, R.I., July 27, 2022 /PRNewswire/ -- Embrace Home Loans, a top-ranked national mortgage lender, announces that Lisbeth Najarro, a senior loan officer at the company's Fairfax, Virginia office, has been named one of the top 100 Latino mortgage originators in the Southeast region by the National Association of Hispanic Real Estate Professionals (NAHREP).

Key Points: 
  • The NAHREP Top 100 Latino Mortgage Originators Southeast is part of its Top 250 Latino Mortgage Originators Report, which celebrates leading originators whose exceptional hard work and dedication to homeownership led them to close billions of dollars in mortgages in 2021.
  • The report ranks individual originators based on both number and dollar volume of transactions and represents$17.3 billion in combined mortgage sales in 2021.
  • "I'm delighted to be named a top Latino originator," said Najarro.
  • Founded in 1983, Embrace Home Loans is a prominent mortgage lender that provides borrowers and financial institutions with an exceptional mortgage experience.

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, July 26, 2022
Rubius, GLOBE, Twitter, The Boston Globe, Providence Business News, Therapy, News, Cancer, RED, LinkedIn, Nasdaq, Degenerative disease, Red Cell, Pharmaceutical industry, Facebook

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.
  • The company will not be hosting a teleconference in conjunction with its financial results press release.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

Retrieved on: 
Thursday, July 14, 2022
Rubius, SEC, Marketing, Novartis, U.S. Securities and Exchange Commission, Autoimmunity, Annual report, Immunology, AAA, Providence Business News, Lung, Therapy, LinkedIn, The Boston Globe, RED, Patient, GLOBE, COVID-19, Breast, Private Securities Litigation Reform Act, Cancer, Red Cell, Nasdaq, Degenerative disease, Hematology, Transplant, News, Twitter, University, El Rubius, Pharmaceutical industry, Organic chemistry, Facebook, Chemistry

Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.

Key Points: 
  • Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.
  • Susannes deep knowledge in oncology drug development and commercialization will be instrumental as we continue to advance our oncology pipeline of Red Cell Therapeutics, including RTX-240 and RTX-224 for the treatment of solid tumors.
  • I am thrilled to welcome Susanne to the Rubius board of directors, said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.